THROMBOTIC THROMBOCYTOPENIC PURPURA, ACQUIRED
Clinical trials for THROMBOTIC THROMBOCYTOPENIC PURPURA, ACQUIRED explained in plain language.
Never miss a new study
Get alerted when new THROMBOTIC THROMBOCYTOPENIC PURPURA, ACQUIRED trials appear
Sign up with your email to follow new studies for THROMBOTIC THROMBOCYTOPENIC PURPURA, ACQUIRED, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for rare blood disorder: daratumumab under study
Disease control Recruiting nowThis study looks at how well the drug daratumumab works for people with a rare blood clotting disorder called immune-mediated thrombotic thrombocytopenic purpura (iTTP) when standard treatments fail. Researchers will track 40 patients to see if the drug helps restore normal blood…
Matched conditions: THROMBOTIC THROMBOCYTOPENIC PURPURA, ACQUIRED
Sponsor: Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico • Aim: Disease control
Last updated May 26, 2026 10:21 UTC
-
Gene hunt: could your DNA predict TTP relapse?
Knowledge-focused Recruiting nowThis study looks at whether a specific gene (TNFAIP3) is linked to immune-mediated thrombotic thrombocytopenic purpura (iTTP), a rare blood disorder. Researchers will compare 400 people with iTTP to healthy volunteers to see if gene variations affect disease risk and relapse. The…
Matched conditions: THROMBOTIC THROMBOCYTOPENIC PURPURA, ACQUIRED
Phase: NA • Sponsor: Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico • Aim: Knowledge-focused
Last updated Apr 26, 2026 19:39 UTC